Oncosil Medical Ltd (OSL)
Australian Securities Exchange · Australia · prices in AUD · close of 20 Oct 2026
Key indicators
| Last close | AUD 0.815 |
|---|---|
| 52-week range | 0.370 – 1.640 |
| Return, 1 month / 3 months | −11.9% / −37.3% |
| Return, 1 year / 3 years | −47.6% / −73.0% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 47 |
| Volatility (1 year) | 95.8% |
| Worst drawdown (1 year) | -74.7% |
| Average daily value traded | 0.15M AUD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
OncoSil Medical is an Australian medical device company that develops a targeted radiation treatment for people with pancreatic cancer. Its product is a radioactive implant placed directly into a pancreatic tumour through an endoscopic procedure, designed to deliver a local dose of radiation to the cancer while sparing surrounding healthy tissue. The company works with clinicians and hospitals that treat pancreatic cancer, and it is based in Australia.
The shares are listed on the Australian Securities Exchange in Australia under the code OSL, and the price on this page is in Australian dollars (AUD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Oncosil Medical Ltd (OSL) trades on the Australian Securities Exchange in Australia. It last closed at AUD 0.815 on 20 October 2026.
Its price-based Market X-Ray is 50 out of 100 (a weak price profile), ranking 931 of 1,815 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 47.6% and over the last three months it fell 37.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Australian Securities Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 74 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 4.2% | ||
| From 52-week high | -47.2% | ||
| Momentum | 44 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -37.3% | ||
| 6-month return | 68.0% | ||
| 12-month return, skipping the last month | -40.5% | ||
| Stability (higher is calmer) | 22 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 95.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -74.7% | ||
| Liquidity | 66 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.15M AUD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
Weak spots
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +14.8% |
|---|---|
| 1 month | −11.9% |
| 3 months | −37.3% |
| 6 months | +68.0% |
| 1 year | −47.6% |
| 3 years | −73.0% |
| 5 years | −94.8% |
Signals
| 50-day / 200-day average | 0.968 / 0.782 |
|---|---|
| Golden / death cross (60 days) | Golden, 57 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.051 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Australian Securities Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.